AssetMark Inc’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

AssetMark Inc’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10	Closed	–	–	1531
2016 Q4	$0	Buy	+10	New	+$100	﹤0.01%	1451

Other funds holding SCLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AssetMark Inc's SCLN Position: Q1 2017 in Review

AssetMark Inc sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2017, closing a stake of 10 shares.

AssetMark Inc first reported a position in SCLN in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 136 funds tracked by Wall St. Rank hold SCLN as of Q1 2017.

AssetMark Inc reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
AssetMark Inc sold 10 Sciclone Pharmaceuticals Inc shares in Q1 2017.
AssetMark Inc first reported a position in Sciclone Pharmaceuticals Inc in Q4 2016 and held it in 1 quarter.
AssetMark Inc's Sciclone Pharmaceuticals Inc position peaked at $0 in Q4 2016.
136 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2017.

Based on AssetMark Inc's 13F filing for Q1 2017, filed 9 May 2017.